Your session is about to expire
← Back to Search
Tirzepatide vs Dulaglutide for Type 2 Diabetes (SURPASS-CVOT Trial)
SURPASS-CVOT Trial Summary
This trial is testing a new diabetes medication to see if it is more effective and safe than another existing diabetes medication.
SURPASS-CVOT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSURPASS-CVOT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 210 Patients • NCT05024032SURPASS-CVOT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with type 2 diabetes.I have a known issue with my stomach emptying or have had/planning stomach surgery.I or my family have a history of MTC or MEN-2.I have not had a blood transfusion or severe blood loss in the last 3 months.I have been in remission for less than 5 years or have an active cancer.I am scheduled for a procedure to improve blood flow to my heart, neck, or limbs.I have had pancreatitis before.I have been diagnosed with heart disease caused by hardened arteries.I have had severe low blood sugar or didn't notice it happening in the last 6 months.I have had ketoacidosis or a severe hyperglycemic state before.I am planning treatment for eye conditions related to diabetes.You are considered overweight based on your height and weight.I had a major heart problem in the last 60 days.Your HbA1c level is between 7.0% and 10.5%.I have type 1 diabetes.
- Group 1: Tirzepatide
- Group 2: Dulaglutide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any short or long-term dangers associated with taking Tirzepatide?
"This Tirzepatide study is classified as a Phase 3 trial, which means that while there is efficacy data available, the focus is on further confirming safety through multiple rounds of testing."
How many study participants are needed for this clinical trial?
"This clinical trial is not recruiting patients at this moment. The last update to the study was on October 3rd, 2022. However, there are 1508 other trials related to type 2 diabetes mellitus and 19 for Tirzepatide that are actively looking for participants."
Are there other scientific investigations that have studied Tirzepatide?
"Tirzepatide is being studied in 19 separate clinical trials, 9 of which are in Phase 3. The trial locations for Tirzepatide are primarily situated in Qinhuangdao, Hebei; but there are a total of 1597 active sites for these medical studies."
How many total facilities are needed to manage this clinical trial?
"There are over 100 medical facilities enrolling patients in this clinical trial, including Cardiology Partners Clinical Research Institute, LLC in Wellington, Florida, L-MARC Research Center in Louisville, Kentucky, and Cardiovascular Associates of the Delaware Valley in Haddon Heights, New jersey."
Why is Tirzepatide commonly prescribed?
"Tirzepatide is most often used to control blood sugar levels in patients with type 2 diabetes mellitus. Additionally, this medication can be prescribed to help manage cardiovascular risk factors, diet, and exercise."
Are we still enrolling people for this experiment?
"Although this study is not actively recruiting at the moment, it's still possible to participate. The trial was initially posted on 5/29/2020 and was last edited on 10/3/2022. If you are seeking other studies, there are presently 1508 clinical trials actively recruiting participants with type 2 diabetes mellitus and 19 trials for Tirzepatide actively looking for patients."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger